2. Borlaug, B.A., et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med, 2023. 3. 射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组, 射血分数保留的心力衰竭诊断与治疗中国专家共识2023. 中国循环杂志, 2023...
6.Borlaug BA, Kitzman DW, Davies MJ,et al.Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.Nat Med. 2023;29:2358-2365. doi: 10.1038/s41591-02...
2. Borlaug, B.A., et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med, 2023. 3. 射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组, 射血分数保留的心力衰竭诊断与治疗中国专家共识2023. 中国循环杂志, 2023...
目前尚不清楚,与HF相关的生活质量指标的改善是由减肥驱动的还是独立于此,也可能两种机制均参与其中。 文献索引:Kosiborod MN, et al., on behalf of the STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in Patients...
STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. [2] Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by ...
[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. ...
[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. ...
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints ...
预测:类中东呼吸综合征冠状病毒(middle east respiratory syndrome coronavirus,MERS-CoV)会成为潜在的大流行威胁 ④The Lancet Oncology:Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial 卡博替尼(Cabozantinib)单药用于晚期肾上腺皮质癌的单组、Ⅱ期试验 ...
2. Borlaug, B.A., et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med, 2023. 3. 射血分数保留的心衰诊断与治疗中国专家共识制定工作组, 射血分数保留的心衰诊断与治疗中国专家共识2023. 中国循环杂志, 2023. 38(...